Study Assessing Safety and Efficacy of Buntanetap in Participants With Early Alzheimer's Disease

This study will test if an investigational drug called buntanetap is safe and helpful to people with memory and thinking problems associated with early Alzheimer’s disease (AD).

In order to participate you must meet the following criteria:

• Are between 55 and 85 years of age.
• Have a diagnosis of mild cognitive impairment (MCI) or early Alzheimer's disease (AD).
• Have a study partner (such as a spouse, family member, or close friend) willing and able to attend study visits with you and to answer questions about you to study staff.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.